GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Duo Rui Pharmaceutical Co Ltd (SZSE:301075) » Definitions » Debt-to-Equity

Tibet Duo Rui Pharmaceutical Co (SZSE:301075) Debt-to-Equity : 0.30 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tibet Duo Rui Pharmaceutical Co Debt-to-Equity?

Tibet Duo Rui Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥28.6 Mil. Tibet Duo Rui Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥190.3 Mil. Tibet Duo Rui Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was ¥737.8 Mil. Tibet Duo Rui Pharmaceutical Co's debt to equity for the quarter that ended in Jun. 2024 was 0.30.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SZSE:301075' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.18   Max: 0.37
Current: 0.3

During the past 7 years, the highest Debt-to-Equity Ratio of Tibet Duo Rui Pharmaceutical Co was 0.37. The lowest was 0.03. And the median was 0.18.

SZSE:301075's Debt-to-Equity is ranked better than
50.36% of 838 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs SZSE:301075: 0.30

Tibet Duo Rui Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Duo Rui Pharmaceutical Co Debt-to-Equity Chart

Tibet Duo Rui Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial 0.23 0.15 0.03 0.14 0.23

Tibet Duo Rui Pharmaceutical Co Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.23 0.23 0.37 0.30

Competitive Comparison of Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity falls into.



Tibet Duo Rui Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tibet Duo Rui Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Tibet Duo Rui Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Duo Rui Pharmaceutical Co  (SZSE:301075) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Tibet Duo Rui Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Tibet Duo Rui Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Duo Rui Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Biomedical Park, Area A, 3rd Floor, Building 1, Changdu Economic Development Zone, Tibet Autonomous Region, Tibet, CHN, 854000
Duo Rui Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chemical pharmaceutical preparations and their raw materials.

Tibet Duo Rui Pharmaceutical Co Headlines

No Headlines